IV methylprednisolone was linked to a small change in proptosis from baseline compared with placebo in patients with thyroid eye disease, while teprotumumab may improve proptosis and diplopia vs. IV methylprednisolone.
Treatment options to improve proptosis and diplopia in thyroid eye disease are limited. Recent guidelines recommend IV methylprednisolone for most patients with moderate to severe active thyroid eye disease, but the dose, timing and duration of therapy vary in the literature. Tepezza (teprotumumab, Horizon Therapeutics) is FDA approved for thyroid eye disease but has not been